MetroWilms
Phase 1/2 Recruiting
28 enrolled
SCOTI
Phase 2 Recruiting
50 enrolled
Combination Therapy in Cancers With Mutations in DNA Repair Genes
Phase 1 Recruiting
24 enrolled
METTSEO
Phase 1 Recruiting
15 enrolled
I-SPY
Phase 2 Recruiting
5,000 enrolled
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)
Phase 1 Recruiting
20 enrolled
TRIBE-C
Phase 3 Recruiting
528 enrolled
PANCREAS
Phase 2 Recruiting
84 enrolled
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Phase 1/2 Recruiting
77 enrolled
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Phase 3 Recruiting
382 enrolled
FOBEAR
Phase 3 Recruiting
582 enrolled
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Phase 1/2 Recruiting
104 enrolled
MEMMAT
Phase 2 Recruiting
232 enrolled
Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma
Phase NA Recruiting
20 enrolled
AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma
Phase 2 Recruiting
12 enrolled
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
Phase 2 Recruiting
45 enrolled
SMART TNT
Phase 1 Recruiting
25 enrolled
Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
Phase 1/2 Recruiting
35 enrolled
Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: A Single-arm, Phase I/II,Multi-center, Clinical Study.
Phase 1/2 Recruiting
125 enrolled
CAPRI-3 GOIM
Phase 3 Recruiting
480 enrolled
LAP100
Phase 3 Recruiting
356 enrolled
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
Phase 2 Recruiting
25 enrolled
NB-NK-2026
Phase 3 Recruiting
5 enrolled
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
Phase 1/2 Recruiting
90 enrolled
ESMART
Phase 1/2 Recruiting
472 enrolled
5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.
Phase 1/2 Recruiting
27 enrolled
PANC
Phase 2 Recruiting
125 enrolled
Aflac-NBL-2002
Phase 1 Recruiting
24 enrolled
VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
Phase 1/2 Recruiting
23 enrolled
Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)
Phase 1/2 Recruiting
42 enrolled
CEIL
Phase 2 Recruiting
198 enrolled
VICTORIA
Phase 2 Recruiting
130 enrolled
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
Phase NA Recruiting
178 enrolled
AIO-KRK-0418
Phase 3 Recruiting
507 enrolled
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Phase 1 Recruiting
49 enrolled
AtezoTRIBE2
Phase 3 Recruiting
238 enrolled
Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.
Phase 2 Recruiting
38 enrolled
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
Phase 2 Recruiting
20 enrolled
GRACIE
Phase 2 Recruiting
88 enrolled
A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors
Phase 1 Recruiting
48 enrolled
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
Phase 2 Recruiting
62 enrolled
The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer
Phase 1/2 Recruiting
40 enrolled
I-FLOAT
Phase 1 Recruiting
54 enrolled
Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer
Phase 2 Recruiting
20 enrolled
Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI
Phase 1/2 Recruiting
10 enrolled
The Sagittarius Trial
Phase 3 Recruiting
700 enrolled
PTCA199-11
Phase 3 Recruiting
210 enrolled
OPTICAL-2
Phase 2 Recruiting
143 enrolled
Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
Phase 1 Recruiting
18 enrolled
OSCAR
Phase 3 Recruiting
348 enrolled